Galion reported on September 6th that zhejiang yatai pharmaceutical (002370.SZ) announced that the company recently received the acceptance notice of the consistency evaluation of Atorvastatin tablets issued by the National Medical Products Administration. Atorvastatin tablets are mainly used to treat hypertension, angina, myocardial infarction, and can also be used for arrhythmia, hyperthyroidism, and pheochromocytoma.
亚太药业(002370.SZ)：收到阿替洛尔片一致性评价受理通知书
Zhejiang Yatai Pharmaceutical (002370.SZ): Received the acceptance notice of the consistency evaluation of Atorvastatin tablets.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated